Clinical Trial Search

Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -6.52; -6 units on a scale

Primary: Change in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score as Compared to Placebo From Double-Blind Baseline to Week 6 (Day 43) Baseline — 59.2…

Primary: 6-month Acute Cellular-mediated Rejection Rate (CMR) — 14; 20 Participants

Primary: Partial Mayo Score: Change From Baseline Over Time — 2.5; -0.2; -0.4; -0.5 units on a scale

Primary: Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism — 13; 17; 50; 8 participants — p=0.0001

Primary: Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 150 mg Dose Group and Matched Placebo — 6.2; -57.2…

Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…

Primary: Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies — 58 Participants

Primary: Time to Progression — 8.68; 6.84 months — p=0.1224

Primary: D. Farinae Specific IgG4 Change From Baseline to End of Treatment — 0.473; -0.01 mg antibody/ml

Primary: Number of Subjects With rSBA-MenC, rSBA-MenA, rSBA-MenW-135, rSBA-MenY Titers Greater Than or Equal to (≥) the Cut-off Values — 360; 353; 23; 357 Participants

Primary: Ocular Surface Disease Index (OSDI©) Questionnaire — 19.3; 19.3; 7.3; 7.9 points

Primary: Nitazoxanide — 27 participants

Primary: Change From Baseline to Week 104 for the Participant's Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain and Function (Sports and Recreational Activities) Scores…

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 95.3; 90.5; 97.7; 97.6 percentage of participants